Muscat, Oman – February 2, 2025 – In a major step toward enhancing pharmaceutical self-sufficiency, Opal BioPharma has signed a Local Content Commitment Agreement with the Ministry of Health (MOH) and Nazdahar. This strategic collaboration aligns with Oman Vision 2040, reinforcing efforts to localize biopharmaceutical production, reduce dependence on imports, and foster innovation in the healthcare sector.
The agreement, signed during the National Local Content Laboratory closing ceremony, represents a crucial investment in building a resilient, technology-driven pharmaceutical industry in Oman. Speaking on behalf of the Ministry of Health, His Excellency Suleiman bin Nasser Al-Hajji, Undersecretary for Administrative and Financial Affairs, emphasized the government’s commitment to supporting local manufacturers:
“By working with national pharmaceutical companies like Opal BioPharma, we are ensuring the availability of essential medicines, strengthening Oman’s healthcare sector, and fostering economic diversification. Localizing production is a strategic priority that enhances our nation’s ability to meet future healthcare demands.”
Opal BioPharma’s Vision for a Self-Sufficient Healthcare Sector
As a key player in Oman’s biopharmaceutical industry, Opal BioPharma will leverage this agreement to:
- Develop domestic production capabilities for specialized biopharmaceuticals
- Invest in research collaborations and technology transfer
- Strengthen partnerships with regulators to ensure high-quality local manufacturing
- Support local suppliers to create a sustainable, innovation-driven supply chain
Chairman Saad Al Junaibi stated:
“We are the first GCC pioneers in the region to have an end-to-end product that does not fill and pack. We are considering establishing ourselves as a local company to provide health and economic security for Oman. We are the only one now. I don’t know whether others will be in the region, but Oman will have the first biopharma industry.”
Aligning with Oman Vision 2040
The localization of pharmaceutical production plays a vital role in Oman’s long-term healthcare sustainability strategy, supporting:
- Enhanced access to life-saving medications
- Economic diversification through healthcare innovation
- Development of a highly-skilled national workforce in pharmaceutical sciences
A Transformative Step for Oman’s Biopharmaceutical Landscape
Through this agreement, Opal BioPharma is set to:
- Expand its biomanufacturing infrastructure
- Accelerate innovation in biotechnology and gene therapy
- Strengthen its role as a strategic healthcare partner to the government
With this initiative, Opal BioPharma is advancing local content in healthcare and shaping Oman’s future as a leader in biopharmaceutical excellence.
References:
https://x.com/OmaniMOH/status/1886108578550849727
